TC
BIIB icon

TFS Capital’s Biogen BIIB Stock Holding History

TFS Capital’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,711
Closed -$464K – 44
2017
Q2 		$464K Sell
1,711
-78
-4% -$20.6K 0.18% 183
2017
Q1 		$489K Buy
1,789
+147
+9% +$41.6K 0.16% 186
2016
Q4 		$466K Buy
+1,642
New +$487K 0.12% 280
2016
Q3 		– Sell
-1,329
Closed -$321K – 757
2016
Q2 		$321K Buy
+1,329
New +$350K 0.06% 578
2014
Q2 		– Sell
-876
Closed -$268K – 1133
2014
Q1 		$268K Buy
+876
New +$278K 0.02% 1074

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TFS Capital's BIIB Position: Q3 2017 in Review

TFS Capital sold out of Biogen (BIIB) in Q3 2017, closing a stake of 1,711 shares — an estimated $464K sold.

TFS Capital first reported a position in BIIB in Q1 2014 and held it in 5 quarters. The position peaked at $489K in Q1 2017. 1,014 funds tracked by Wall St. Rank hold BIIB as of Q3 2017.

  • TFS Capital reported no remaining Biogen position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 1,711 Biogen shares in Q3 2017, an estimated $464K.
  • TFS Capital first reported a position in Biogen in Q1 2014 and held it in 5 quarters.
  • TFS Capital's Biogen position peaked at $489K in Q1 2017.
  • 1,014 funds tracked by Wall St. Rank held Biogen as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.